A comparative analysis of SRT and SRS in the treatment of brain metastases from lung adenocarcinoma
Li Yong1, Liu Fenghua2, Liang Kangning1, Shao Xianjun1, Zhang Li1, Liang Xiaohua3, Pan Mianshun1
1Center of Radiation Oncology,Shanghai Wujing Hospital,Shanghai 201103,China; 2Center of Radiation Oncology,The Third Affiliated Hospital of Naval Military Medical University,Shanghai 201805,China; 3Department of Oncology,Huashan Hospital Affiliated to Fudan University,Shanghai 200040,China
Abstract：Objective To compare the clinical efficacy of stereotactic radiotherapy (SRT) and stereotactic radiosurgery (SRS) in the treatment of brain metastases from January 2006 to December 2016,lung adenocarcinoma and analyze the related factors. Methods In this multi-center retrospective analysis, clinical data of 208 patients with brain metastases from lung adenocarcinoma were retrospectively analyzed and assigned into the SRT (n=86) and SRS groups (n=122). The clinical characteristics of patients in two groups were analyzed. The local tumor control rate,median survival time and radiation brain injury were statistically compared between two groups. Results At the end of follow-up,the Objective response rates (ORR) were 70.9% and 71.3% in the SRT and SRS groups (P=0.772). The local tumor control rates at 12 months were 89% and 86% in the SRT and SRS groups (P=0.383). The median overall survival time of all patients was 14.3 months,15.6 months in the SRT group and 13.7 months in the SRS group (P=0.349). Multivariate analysis showed that large target volume (P<0.001),low GPA score (P=0.012) and no insensitive gene mutation (P<0.001) were the main factors of poor prognosis. The incidence of late radiation brain injury was 5.8% and 14.8% in two groups (P=0.043). Conclusions SRT and SRS yield similar clinical efficacy in the treatment of brain metastases from lung adenocarcinoma. SRT may have a lower incidence of late radiation brain injury than SRS.
Li Yong,Liu Fenghua,Liang Kangning et al. A comparative analysis of SRT and SRS in the treatment of brain metastases from lung adenocarcinoma[J]. Chinese Journal of Radiation Oncology, 2020, 29(2): 88-92.
[1] Preusser M,Capper D,Ilhan-Mutlu A,et al. Brain metastases:pathobiology and emerging targeted therapies[J]. Acta Neuropathol,2012,123(2):205-222. DOI:10.1007/s00401-011-0933-9.
[2] Lehrer EJ,Peterson JL,Zaorsky NG,et al. Single versus multifraction stereotactic radiosurgery for large brain metastases:an international Meta-analysis of 24 trials[J]. Int J Radiat Oncol Biol Phys,2019,103(3):618-630. DOI:10.1016/j.ijrobp.2018.10.038.
[3] Sheehan JP,Yen CP,Lee CC,et al. Cranial stereotactic radiosurgery:current status of the initial paradigm shifter[J]. J Clin Oncol,2014,32(26):2836-2846. DOI:10.1200/JCO.2013.53.7365.
[4] Chao ST,Ahluwalia MS,Barnett GH,et al. Challenges with the diagnosis and treatment of cerebral radiation necrosis[J]. Int J Radiat Oncol Biol Phys,2013,87(3):449-457. DOI:10.1016/j.ijrobp.2013.05.015.
[5] 潘绵顺,李勇,邱书珺,等. SRT联合贝伐珠单抗治疗肺腺癌脑转移瘤的疗效评估[J]. 中华放射肿瘤学杂志,2017,26(8):880-883. DOI:10.3760/cma.j.issn.1004-4221.2017.08.007.
Pan MS,Li Y,Qiu SJ,et al. Efficacy and safety of stereotactic radiotherapy combined with bevacizumab for brain metastases of lung adenocarcinoma[J]. Chin J Radiat Oncol,2017,26(8):880-883. DOI:10.3760/cma.j.issn.1004-4221.2017.08.007.
[6] Minniti G,Scaringi C,Paolini S,et al. Single-fraction versus multifraction (3×9 Gy) stereotactic radiosurgery for large (>2 cm) brain metastases:a comparative analysis of local control and risk of rRadiation-induced brain necrosis[J]. Int J Radiat Oncol Biol Phys,2016,95(4):1142-1148. DOI:10.1016/j.ijrobp.2016.03.013.
[7] Lucia F,Key S,Dissaux G,et al. Inhomogeneous tumor dose distribution provides better local control than homogeneous distribution in stereotactic radiotherapy for brain metastases[J]. Radiother Oncol,2019,130:132-138. DOI:10.1016/j.radonc.2018.06.039.
[8] 潘绵顺,李勇,邱书珺,等. 贝伐单抗治疗放射性脑坏死初步疗效分析[J]. 中华放射肿瘤学杂志,2015,24(4):434-437. DOI:10.3760/j.issn.1004-4221.2015.04.028.
Pan MS,Li Y,Qiu SJ,et al. Preliminary efficacy of bevacizumab for cerebral radiation necrosis[J]. Chin J Radiat Oncol,2015,24(4):434-437. DOI:10.3760/j.issn.1004-4221.2015.04.028.
[9] Mulvenna P,Nankivell M,Barton R,et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ):results from a phase 3,non-inferiority,randomised trial[J]. Lancet,2016,388(10055):2004-2014. DOI:10.1016/S0140-6736(16)30825-X.
[10] Qin H,Wang C,Jiang Y,et al. Patients with single brain metastasis from non-small cell lung cancer equally benefit from stereotactic radiosurgery and surgery:a systematic review[J]. Med Sci Monit,2015,21(1):144-152. DOI:10.12659/MSM.892405.
[11] Aoyama H,Shirato H,Tago M,et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs.stereotactic radiosurgery alone for treatment of brain metastases:a randomized controlled trial[J]. JAMA,2006,295(10):2483-2491. DOI:10.1001/jama.295.21.2483.
[12] Kocher M,Soffietti R,Abacioglu U,et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases:results of the EORTC 22952-26001 study[J]. J Clin Oncol,2011,29:134-141. DOI:10.1200/JCO.2010.30.1655.
[13] Fokas E,Henzel M,Surber G,et al. Stereotactic radiosurgery and fractionated stereotactic radiotherapy:comparison of efficacy and toxicity in 260 patients with brain metastases[J]. J Neurooncol,2012,109(1):91-98. DOI:10.1007/s11060-012-0868-6.
2020, Vol. 29 
